We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

251 hedge funds and large institutions have $4.98B invested in Iovance Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 98 increasing their positions, 77 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $37.9M | Put options by funds: $18.9M

27% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 77

5.5% more ownership

Funds ownership: 101.41% → 106.9% (+5.5%)

7% less funds holding

Funds holding: 269 → 251 (-18)

28% less capital invested

Capital invested by funds: $6.9B → $4.98B (-$1.92B)

29% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 58

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
251
Holders Change
-18
Holders Change %
-6.69%
% of All Funds
4.41%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
41
Increased
98
Reduced
77
Closed
58
Calls
$37.9M
Puts
$18.9M
Net Calls
+$18.9M
Net Calls Change
-$23.1M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$184M
2
Deutsche Bank
Deutsche Bank
Germany
+$181M
3
CS
Credit Suisse
Switzerland
+$98.2M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$67.8M
5
Goldman Sachs
Goldman Sachs
New York
+$48.6M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$93.1M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$86.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$53.9M
4
FCM
Farallon Capital Management
California
-$51.8M
5
CCM
Consonance Capital Management
New York
-$38.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
251
Sphera Funds Management
Israel
– -$5.91M -127,289 Closed
CM
252
Castleark Management
Illinois
– -$5.06M -109,000 Closed
MAP
253
Moody Aldrich Partners
Massachusetts
– -$4.69M -101,161 Closed
6CM
254
683 Capital Management
New York
– -$4.64M -100,000 Closed
HF
255
HRT Financial
New York
– -$3.76M -80,965 Closed
Thrivent Financial for Lutherans
256
Thrivent Financial for Lutherans
Minnesota
– -$2.19M -47,128 Closed
ECM
257
ExodusPoint Capital Management
New York
– -$2.12M -45,671 Closed
Prudential Financial
258
Prudential Financial
New Jersey
– -$1.85M -39,945 Closed
WI
259
WBI Investments
New Jersey
– -$1.7M -36,566 Closed
Verition Fund Management
260
Verition Fund Management
Connecticut
– -$962K -20,742 Closed
FAM
261
Fred Alger Management
New York
– -$873K -18,822 Closed
Axa
262
Axa
France
– -$775K -16,700 Closed
WG
263
Winton Group
United Kingdom
– -$708K -15,264 Closed
GT
264
Glenmede Trust
Pennsylvania
– -$696K -15,009 Closed
M&T Bank
265
M&T Bank
New York
– -$640K -13,786 Closed
FC
266
FORA Capital
Florida
– -$618K -13,314 Closed
SAM
267
Shell Asset Management
Netherlands
– -$583K -12,574 Closed
AG
268
Algert Global
California
– -$539K -11,621 Closed
BCI
269
Brinker Capital Investments
Pennsylvania
– -$502K -10,818 Closed
PP
270
Paloma Partners
Connecticut
– -$499K -10,737 Closed
SCM
271
Silverarc Capital Management
Massachusetts
– -$464K -10,000 Closed
MF
272
Magnetar Financial
Illinois
– -$418K -9,004 Closed
IA
273
IndexIQ Advisors
New York
– -$325K -6,997 Closed
PAM
274
Premier Asset Management
Illinois
– -$323K -6,951 Closed
RJFSA
275
Raymond James Financial Services Advisors
Florida
– -$321K -6,924 Closed
9 10
11
12 13

IOVA Hedge Fund Activity: Q1 2021 in Review

251 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2021, worth a combined $4.98B — down 28% from $6.9B a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of IOVA and 41 opened new positions — a net loss of 17 holders — while 77 trimmed existing stakes and 98 added.

The largest buyer was ARK Investment Management, adding an estimated $184M. The largest seller was T. Rowe Price Associates, cutting an estimated $93.1M.

  • 251 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2021, down from 269 in Q4 2020.
  • Funds reported $4.98B of Iovance Biotherapeutics stock for Q1 2021, down 28% quarter-over-quarter.
  • 41 funds opened new Iovance Biotherapeutics positions in Q1 2021 and 58 closed out, a net change of -17 holders.
  • The largest Iovance Biotherapeutics buyer in Q1 2021 was ARK Investment Management, an estimated $184M added.
  • The largest Iovance Biotherapeutics seller in Q1 2021 was T. Rowe Price Associates, an estimated $93.1M sold.

Based on aggregated 13F filings for Q1 2021.